Poliomyelitis leading to large-scale trials in the then Belgian Congo and the vaccination of seven million children in Poland against serotypes PV1 and PV3 between 1958 and 1960. The second inactivated polio virus vaccine was developed in 1952 by Jonas Salk at the University of Pittsburgh, and announced to the world on 12 April 1955. The Salk vaccine, or inactivated poliovirus vaccine, is based on poliovirus grown in a type of monkey kidney tissue culture (vero cell line), which is chemically inactivated with formalin. After two doses of inactivated poliovirus vaccine (given by injection), 90 percent or more of individuals develop
Salk Institute for Biological Studies draw the best researchers in the world. Salk and Kahn – having both descended from Russian Jewish parents that had immigrated to the United States – had a deeper connection than just mere partners on an architectural project. The results of their connection is seen in the design that resulted from their collaboration. The original buildings of the Salk Institute were designated as a historical landmark in 1991. The entire site was deemed eligible by the California Historical Resources Commission in 2006 for listing on the National Register of Historic Places. The institute has three Nobel laureates on its faculty: